Genetic Screening of Patients with Thyrotoxic Hypokalemic Periodic Paralysis: An Experience from a Tertiary Care Hospital in the Northeast of Brazil.

Autor:	Gbefon CY; Clinical Research Center of the University Hospital of the Federal University of Maranhão (CEPEC - HUUFMA), São Luís,Brazil., Sobral CPS; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Caldas A; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Rocha VCC; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Azulay RSS; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Nascimento GC; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Damianse SSP; Research Group in Clinical and Molecular Endocrinology and Metabology (ENDOCLIM), São Luís,Brazil., Gaspar SAS; Clinical Research Center of the University Hospital of the Federal University of Maranhão (CEPEC - HUUFMA), São Luís,Brazil., Faria MS; Clinical Research Center of the University Hospital of the Federal University of Maranhão (CEPEC - HUUFMA), São Luís,Brazil., Magalhães M; Clinical Research Center of the University Hospital of the Federal University of Maranhão (CEPEC - HUUFMA), São Luís,Brazil.
Jazyk:	angličtina
Zdroj:	Endocrine, metabolic & immune disorders drug targets [Endocr Metab Immune Disord Drug Targets] 2021; Vol. 21 (12), pp. 2231-2237.
DOI:	10.2174/1871530321666210719114937
Abstrakt:	Background: Thyrotoxic Hypokalemic Periodic Paralysis (THPP) is a rare neuromuscular disease characterized by recurrent episodes of skeletal muscle weakness associated with hypokalemia. Alterations in protein-encoding genes that are part of ion channels seem to be related to the development of this disease. However, the pathogenic potential of some variants in these genomic regions is not yet fully understood. The aim of this study was to screen genetic alterations in regions coding for calcium (cav1.1), sodium (nav1.4), and potassium (Kir2.6) channels, evaluating its impact on the phenotype of patients with THPP. Methods: Four patients with a diagnosis of THPP followed by the Endocrinology Service of the University Hospital of the Federal University of Maranhão (Brazil) were investigated for the presence of molecular abnormalities in CACNA1S, SCN4A, and KCNJ18 genes. Results: The KCNJ18 analysis revealed at least one polymorphic variant in each patient. Considering the haplotypic classification of R39Q, R40H, A56E, and I249V variants, two cases were named Kir2.6_RRAI and the other two patients were named Kir2.6_QHEV. No patient had point mutations in the regions evaluated for CACNA1S and SCN4A genes. Conclusion: The identification of the Kir2.6_RRAI and Kir2.6_QHEV haplotypes reinforces the existence of two main haplotypes involving these four loci of the KCNJ18gene. On the other hand, point mutations in CACNA1S, SCN4A, and KCNJ18 genes do not seem to be the main mechanism of pathogenesis of THPP, indicating that many questions about this topic still remain unclear. So, the diagnosis of this rare disorder should still be based on clinical and biochemical aspects presented by the patient. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu